explore -WSS

explore

author：knowledge 2025-10-01 23:03:46 - browse：44

Gene therapy helped Conner Curran, right, walk, but as the drug fades, his family is supporting scientific efforts to allow him and other boys get a second dose. -- Biotech coverage from STAT — Gene therapy helped Conner Curran (at right) walk, but as the drug fades, his family is supporting scientific efforts to allow him and other boys get a second dose. Courtesy Jess & Chris Curran

In the beginning, Conner Curran ran up the stairs.

It was a miraculous moment for him and his parents, Jess and Chris Curran. Just months before, contractors were in their New York home to install a motorized lift, while Jess tearfully explained that it wasn’t for a grandparent but for their 7-year-old son, who suffered from Duchenne muscular dystrophy and could barely haul himself up the steps.

Then Conner was accepted as the first patient in Pfizer’s Duchenne gene therapy trial. Three weeks later, he could bound to the second floor. Soon, he could walk the two-plus miles to Goldberg’s, a local bagel shop. “I couldn’t do that before,” he told NPR in 2020.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： Eight reasons why you should get an updated Covid vaccine

Wikipedia

WSS

The Readout: Biogen, Guardant, AstraZeneca, H5N1 vaccine

How doctors and nurses shape Google's AI

Female surgeons have lower rates of long

The Readout: Biogen, Guardant, AstraZeneca, H5N1 vaccine

Study finds gene variants tied to breast cancer risk in Black women

Biogen joins immunology wave with $1.15 billion acquisition of HI

hotspot

explore

explore

Hollywood unions extend contract negotiations for actors

Digital health: a case of mistaken identity

23andMe had bad news about my health. I wish a person had delivered it

STAT Readout: Today's biotech news includes Sana and Amylyx

Malaria cases in Florida and Texas: Here’s what you need to know

Making the case for fair compensation in clinical trials

At least 13 dead in Texas as scorching temps continue

Eight reasons why you should get an updated Covid vaccine

Psychedelics group wrestles with new pharma identity

Wellcome Trust names Røttingen as its new CEO

focus

Readout Newsletter: Eli Lilly, AstraZeneca, Bristol Meyers Squibb

There’s no way to know how good AI health technologies are

Biogen joins immunology wave with $1.15 billion acquisition of HI

Readout Newsletter: Eli Lilly, AstraZeneca, Bristol Meyers Squibb

Questions and answers about ramping up H5N1 bird flu vaccine

STAT Readout: Today's biotech news includes Sana and Amylyx

explore

hotspot

Wikipedia

leisure time